Aquilon Pharma revolutionizes the efficacy of inhaled drugs
Who is Aquilon Pharma?
What does Aquilon Pharma have in common with golf?
We develop HP-Betadex-based formulations whose particles of active substance will reach precisely their action site to ensure a better treatment efficiency.
Belgian PharmaTech company with global ambitions
Start-up company, established in 2013
Independent spin-off of Liège University, Belgium
Engaged in the improvement of the efficacy of inhaled drugs
Multidisciplinary approach
Mission
Aquilon Pharma’s endeavour is to improve the efficacy of known inhaled drugs and to make other drugs available by inhalation.
Ambition
Aquilon Pharma aims to improve patient care through continuous innovation in the field of inhaled drugs and improvement of local bioavailability of inhaled drugs.
Vision
Redefining the treatment of lung diseases through revolutionary innovations that meet unmet medical needs.
Values
Reliable, ethical, results-driven, collaborative, creative, quality-driven.
Our core identity
Aquilon Pharma is relying on a panel of World Class thought-leaders and Scientific Advisors
Pr. P. COLOMBO: Expert Pulmonary CMC
Pr. P. DE VUYST: Prev. Head Pulmonary medicine (ULB)
Pr. E. CLAASSEN: Prof. Virology (VUA)
J. KILGOUR: Ex. AZN pulmonary Toxicology
Pr. G. VANDE VELDE: Virology; imaging and experimental animal models (KUL Leuven)
Pr. M. DE RIDDER: Immunology, allergology (ULB Brussels)
Pr. A. YOUNG: Pharmacology, early drug dvpt for respiratory diseases (AYI phama consulting)
P. DORINSKY: Former Head Clinicals GSK /AZN
Pr. M. DECRAMER: Expert in Pulmonary, KUL
P. CAVAILLON: Ex. Head Pulmonary CMC GSK
Pr. A. LUDWIG: Head of pharmacology Aachen Univ.
Dr. R. RUSSELL: Clinical studies in asthma and COPD (Imperial College)
Ph.D. A. DAS: Pulmonary delivery (Pharmaceutical Consulting LLC)
Dr. J. GUIOT: Clinical studies in asthma, COPD, COVID (CHU Liège)
Contact us
Do you have a question? Let's get in touch.